Drs. Alberto Siller and Alberto Garcia run Clínica 0-19 in Monterrey, Mexico, which has become a magnet for patients with diffuse intrinsic pontine glioma (DIPG), a deadly brain cancer. Unfortunately, their treatment is an unproven combination of 11 chemotherapy drugs injected into an artery feeding the brainstem, plus an unknown and unproven “immunotherapy.” Of course it all costs $300,000 or more for a complete course of treatment, and the good doctors are “too busy to do clinical trials” or even publish their survival and recurrence statistics, despite having used this protocol for 20 years. I say: If it quacks like a duck…
Search: “"Stanislaw Burzynski" antineoplastons”
We found 183 results for your search.
I warned you. I’ve been warning you for four years. Now that a federal right-to-try law has passed, the profiteering has begun. Let patients beware!
Share this:
On Wednesday, President Trump signed a federal right-to-try bill into law with great fanfare, making extravagant claims for it. It’s time to reiterate one last time that right-to-try will not help terminally ill patients but it will strip important protections from them. It’s pure snake oil.
Share this:
With the rise of quack stem cell clinics, there has been a rise of crowdfunding campaigns to assist patients in paying for expensive stem cell treatments of unproven efficacy. Unfortunately, as a recent study shows, these crowdfunding campaigns nearly always oversell efficacy and ignore potential risks of the treatments, while making powerful emotional appeals.
Share this:
Recently, the Hope4Cancer Institute, a quack clinic in Mexico has added a treatment known as Rigvir to its other offerings. But what is Rigvir? It turns out that it’s an import from Latvia with a mysterious history. Its proponents claim that it targets cancer specifically. Unfortunately, there is a profound paucity of evidence for its efficacy. The story of Rigvir is the story of an unproven treatment that, because of its origin in a small country, has flown mostly under the radar. Until now, that is.
